Over the years many great oncology leaders have served at the helm as ASCO President. We recognize these individuals here, and extend our gratitude for their service and efforts to champion high-quality cancer care. 2018-2019: Monica M. Bertagnolli, MD 2017-2018: Bruce E. Johnson, MD 2016-2017:...
In a new policy statement, ASCO outlines specific provisions of the 2010 Patient Protection and Affordable Care Act that have the potential to reduce cancer care disparities. ASCO’s statement makes recommendations to ensure that such provisions are carried out effectively, and urges additional...
ASCO recently issued a report, Accelerating Progress Against Cancer: ASCO’s Blueprint for Transforming Clinical and Translational Cancer Research, which outlines the Society’s 10-year plan for improving cancer outcomes. Central to achieving that goal are three steps, including (1) therapy...
Over the past few years, drug shortages in the United States have been on the rise, involving hundreds of agents, many of which are lifesaving medications for patients with cancer. In recent months, the FDA has taken steps to alleviate some of the most critical oncology drug shortages. “We should...
Outcomes for children with cancer have “improved over the course of the years incrementally, mostly not from the development of new drugs, because virtually all the drugs that we use now in leukemia were available in the 1970s. It is really through better understanding of the heterogeneity of the...
Many primary care providers are unaware of the late effects of chemotherapy, according to survey results presented at the ASCO Annual Meeting.1 For three out of four commonly used chemotherapy agents, medical oncologists performed well on the survey, but 29% to 38% of medical oncologists were...
Michael P. Link, MD, 2011–2012 President of ASCO and a pediatric oncologist himself (at Stanford University School of Medicine and the Lucile Salter Packard Children’s Hospital at Stanford), said the crizotinib study by Mosse and colleagues has far-ranging implications. “The molecular driver (ALK)...
Cancer science and information technology are advancing rapidly, but the way we care for patients today cannot fully capitalize on those advances. The proliferation of scientific results and novel treatments is a growing challenge for all oncology professionals as we enter the era of highly...
While the many scientific advances over the past 50 years have led to improved outcomes for millions of patients with cancer—increasing the number of survivors from just 3 million in the 1970s to nearly 14 million today—the next 20 years promise to bring even greater opportunities to improve the...
Serving as ASCO’s President was one of the most exciting years of my professional career. Although that year presented a number of challenges, it also marked a number of accomplishments, including a record number of new ASCO members, which then reached more than 30,000 in 122 countries (today,...